8-K: Biogen Reports Strong First Quarter 2025 Results, Driven by Growth in Key Products

Biogen's first quarter 2025 results show a 6% year-over-year revenue increase, driven by growth in rare disease and launch products, despite a decline in multiple sclerosis revenue.

Summary

• Biogen reported first quarter 2025 total revenue of $2.4 billion, a 6% increase year-over-year.
• GAAP diluted EPS was $1.64, while Non-GAAP diluted EPS was $3.02, which includes a negative impact of ~$0.95 from a $165 million upfront payment to Stoke Therapeutics.
• Product revenue increased 1% year-over-year, with growth in Alzheimer's disease, rare disease, and postpartum depression products more than doubling.
• LEQEMBI global in-market sales reached approximately $96 million, including $52 million in the U.S.
• Global SKYCLARYS revenue was approximately $124 million, with U.S. revenue at $69 million, impacted by Medicare discount dynamics.
• Biogen is updating its full year 2025 guidance to reflect the Stoke payment and favorable foreign exchange, expecting Non-GAAP diluted EPS of $14.50 to $15.50.
• The company expects full year 2025 total revenue to decline by a mid-single digit percentage at constant currency.
• Biogen's Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong revenue growth offset by declining EPS and a forecast for revenue decline in the full year. The focus on new product launches and cost-saving initiatives suggests a positive outlook, but challenges remain.

Positives

• Total revenue increased by 6% year-over-year to $2.4 billion.
• Rare disease revenue increased by 33% at constant currency.
• Launch products in Alzheimer's disease, rare disease, and postpartum depression more than doubled year-over-year.
• LEQEMBI received approval in the E.U., and SKYCLARYS was approved in the U.K. and Brazil.
• The Fit for Growth program is expected to generate significant savings.

Negatives

• GAAP diluted EPS decreased by 39% year-over-year.
• Non-GAAP diluted EPS decreased by 18% year-over-year.
• Multiple sclerosis (MS) product revenue decreased by 11% year-over-year.
• Biosimilars revenue decreased by 8% year-over-year.
• Full year 2025 total revenue is expected to decline by a mid-single digit percentage at constant currency.

Risks

• The company's financial guidance does not include any impact from potential acquisitions or business development transactions, pending and future litigation, or any impact of potential tax or healthcare reform.
• The U.S. and international tariff landscape remains uncertain.
• The company is dependent on revenue from its products and other payments under licensing, collaboration, acquisition or divestiture agreements.
• There is uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products.
• Increased product competition in the biopharmaceutical and healthcare industry could impact results.

Future Outlook

Biogen expects full year 2025 total revenue to decline by a mid-single digit percentage at constant currency, with Non-GAAP diluted EPS of $14.50 to $15.50. The Fit for Growth program is expected to generate significant savings.

Management Comments

• Christopher A. Viehbacher, President and Chief Executive Officer, stated that Biogen delivered strong first-quarter results, supporting their strategy for long-term growth.
• Viehbacher noted that approximately 45% of total product revenue in the first quarter was derived from medicines outside of the MS business.

Industry Context

Biogen's focus on rare diseases and Alzheimer's disease treatments aligns with industry trends towards specialized and high-value therapies. The company's efforts to transform its commercial portfolio reflect a broader industry shift towards diversifying revenue streams and reducing reliance on legacy products.

Comparison to Industry Standards

• Biogen's revenue growth of 6% is comparable to other large-cap biotechnology companies, such as Amgen and Gilead, which have also reported moderate revenue growth in recent quarters.
• LEQEMBI's initial sales of $96 million are in line with expectations for a newly launched Alzheimer's drug, but significantly lower than Eisai's estimates of $150 million.
• The Fit for Growth program's target of $1 billion in gross savings is similar to cost-cutting initiatives undertaken by other pharmaceutical companies, such as Novartis and Sanofi.

Stakeholder Impact

• Shareholders can expect continued investment in new product launches and cost-saving initiatives.
• Employees may be affected by the Fit for Growth program, which aims to streamline operations and reduce costs.
• Patients may benefit from the development and commercialization of new therapies for Alzheimer's disease, rare diseases, and other conditions.

Next Steps

• Biogen plans to host a virtual investor event on June 11th focusing on felzartamab and rare disease.
• The company expects a readout from the Phase 2b LUMA study of BIIB122 for Parkinson's disease in 2026.
• Biogen plans to initiate Phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025.

Key Dates

Keywords

Biogen, Financial Results, First Quarter 2025, Revenue, EPS, LEQEMBI, SKYCLARYS, Rare Disease, Alzheimer's Disease, Guidance, BIIB